Protalix BioTherapeutics advances Fabry disease and gout programs during 2025.
Share this article
Corporate
Score 45
Bullish
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Mar 18, 2026 13:02 UTC
PRBL, BME, XLV
Medium term
Related Articles
Score 85
Meta to Shut Down Horizon Worlds in Major Metaverse Retreat
Mar 18, 15:17
Score 35
Bullish
Morgan Stanley is Bullish on Vistra Corp (VST) Here’s Why
Mar 18, 15:06
Score 65
Bullish
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish
Mar 18, 15:04
Score 78
Bullish
Ocean Power Technologies reports record backlog, lands $6.5M DHS contract
Mar 18, 15:01
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.